STOCK TITAN

Guardant Health Inc - GH STOCK NEWS

Welcome to our dedicated news page for Guardant Health (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Guardant Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Guardant Health's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.81%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.16%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.68%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.76%
Tags
none
Guardant Health Inc

Nasdaq:GH

GH Rankings

GH Stock Data

2.51B
116.66M
4.15%
92.19%
6.37%
Dental Laboratories
Manufacturing
Link
United States
Palo Alto

About GH

we believe conquering cancer is a big data problem. that’s why we built the world’s leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and new products. we’re working on some exciting ones, including in early detection, where the impact on patients can be profound. we’ve raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank.